Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-28T00:13:43.854Z Has data issue: false hasContentIssue false
  • English
  • Français

100 Olanzapine/Samidorphan for Schizophrenia: Weight Gain and Metabolic Outcomes in Phase 3 ENLIGHTEN-2 and Subsequent Long-Term, Open-Label Safety Study

Published online by Cambridge University Press:  24 April 2020

Christoph U. Correll ,
John W. Newcomer ,
Bernard Silverman ,
Lauren DiPetrillo ,
Christine Graham ,
Ying Jiang ,
Yangchun Du ,
Adam Simmons ,
Craig Hopkinson  and
David McDonnell
...Show all authors
Christoph U. Correll
Affiliation:
Medical Director, Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY
John W. Newcomer
Affiliation:
President and Chief Executive Officer, Thriving Mind South Florida, Miami, FL
Bernard Silverman
Affiliation:
Vice President, Clinical Strategy, Alkermes, Inc., Waltham, MA
Lauren DiPetrillo
Affiliation:
Director, Regulatory Affairs, Alkermes, Inc., Waltham, MA
Christine Graham
Affiliation:
Associate Director, Clinical Research, Alkermes, Inc., Waltham, MA
Ying Jiang
Affiliation:
Director, Biostatistics, Alkermes, Inc., Waltham, MA
Yangchun Du
Affiliation:
Senior Director, Biostatistics, Alkermes, Inc., Waltham, MA
Adam Simmons
Affiliation:
Director, Clinical Operations, Alkermes, Inc., Waltham, MA
Craig Hopkinson
Affiliation:
Chief Medical Officer and Senior Vice President, Research and Development Management
David McDonnell
Affiliation:
Executive Medical Director, Clinical Science, Alkermes Pharma Ireland Ltd., Dublin, Ireland
Rene Kahn
Affiliation:
Icahn School of Medicine at Mount Sinai, New York, NY
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

Opioid antagonists may mitigate medication-associated weight gain and/or metabolic dysregulation. ENLIGHTEN-2 evaluated a combination of olanzapine and the opioid antagonist samidorphan (OLZ/SAM) vs olanzapine for effects on weight gain and metabolic parameters over 24 weeks in adults with stable schizophrenia.

METHODS:

This phase 3, double-blind study (ClinicalTrials.gov: NCT02694328) enrolled adults 18–55 yo with stable schizophrenia, randomized 1:1 to once-daily OLZ/SAM or olanzapine. Co-primary endpoints were percent change from baseline in body weight and proportion of patients with ≥10% weight gain at week 24. Waist circumference and fasting metabolic parameters were also measured. Completers could enter a 52-week open-label safety extension.

RESULTS:

561 patients were randomized: 550 were dosed, 538 had ≥1 post-baseline weight assessment, and 352 (64%) completed; 10.9% discontinued due to AEs. At week 24, least squares mean (SE) percent weight change from baseline was 4.21 (0.68)% with OLZ/SAM and 6.59 (0.67)% with olanzapine (difference, −2.38 [0.76]%; P=0.003). Fewer patients treated with OLZ/SAM (17.8%) had ≥10% weight gain vs olanzapine (29.8%; odds ratio=0.50; P=0.003). The change from baseline in waist circumference was significantly smaller with OLZ/SAM (P<0.001). Common AEs (≥10%) with OLZ/SAM and olanzapine were weight increased (24.8%, 36.2%), somnolence (21.2%, 18.1%), dry mouth (12.8%, 8.0%), and increased appetite (10.9%, 12.3%), respectively. Metabolic parameter changes were generally small and remained stable with long-term OLZ/SAM treatment.

DISCUSSION:

OLZ/SAM treatment limited weight gain associated with olanzapine. Metabolic parameter changes were generally small, similar between groups over 24 weeks, and remained stable over an additional 52 weeks of open-label OLZ/SAM treatment.

Funding Acknowledgements:

This study was funded by Alkermes, Inc.

Type
Abstracts
Information
CNS Spectrums , Volume 25 , Issue 2 , April 2020 , pp. 265
Copyright
© Cambridge University Press 2020